Isabelle Cojean-Zelek

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

Karim Fizazi, Laura Faivre, F. Lesaunier et al. · The Lancet Oncology · 2015 · 238 citations

Medicine, Oncology, Urology +17

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Astrid Lièvre, Anthony Turpin, Isabelle Ray‐Coquard et al. · European Journal of Cancer · 2020 · 164 citations · Full text

Medicine, Infectious Diseases, Oncology +14

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Management of cancer in pregnancy: A case of Ewing's sarcoma of the pelvis in the third trimester

Ofer Merimsky, T. Le Chevalier, G. Missenard et al. · Annals of Oncology · 1999 · 57 citations · Full text

Medicine, Obstetrics, Oncology +11

A phase III trial of docetaxel–estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial

Karim Fizazi, F. Lesaunier, R. Delva et al. · European Journal of Cancer · 2011 · 53 citations · Full text

Medicine, Oncology, Pharmacology +14